SEC Form 4 · accession 0001209191-16-106323
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Alan Goldberg
Director
Period of report
Mar 4, 2016
Accepted (ET)
Mar 7, 2016 · 8:03 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001253689
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 4, 2016 | P | 10,397 | $4.7735 | A | 11,497 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common stock was purchased by the reporting person in a series of open market transactions on the transaction date with a volume weighted average purchase price of $4.7735. The range of purchase prices for the transactions reported was $4.61 to $4.924 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.